Systemic Treatment of Hepatobiliary Cancers: From Neoadjuvant Strategies to Advanced Disease

Systemic Treatment of Hepatobiliary Cancers: From Neoadjuvant Strategies to Advanced Disease

Saturday, November 13, 2021
Webinar -- 8:00 AM ET
https://www.clinicaloptions.com/HCCAnaheim2021Join1

Agenda

  • Brief Overview of Hepatobiliary Cancers and Need for Improved Treatments
  • Immunotherapy for Advanced HCC: Current Evidence and Ongoing Trial
  • Systemic Therapy Combinations for Early or Intermediate-Stage HCC
  • Biomarker-Based Targeting of Biliary Tract Cancers
  • Summary and Audience Question and Answer Session

Faculty

Faculty
Richard S. Finn, MD

Professor of Clinical Medicine
Division of Hematology-Oncology
Director, Signal Transduction and Therapeutics Program
Jonsson Comprehensive Cancer Center
David Geffen School of Medicine at UCLA
Los Angeles, California

Faculty
Amit G. Singal, MD, MS

Chief of Hepatology
Medical Director
, Liver Tumor Program
Professor, Department of Internal Medicine
UT Southwestern Medical Center
Dallas, Texas

Faculty
Mark Yarchoan, MD

Assistant Professor
The Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins
Baltimore, Maryland

Goal Statement
The goal of this activity is to improve the knowledge, confidence, competence, and performance of learners to integrate current and emerging therapies into the treatment of patients with hepatocellular carcinoma and biliary tract cancer.

Target Audience
This educational program is intended for hepatologists, medical oncologists, radiation oncologists, surgical oncologists, and other healthcare professionals who treat patients with hepatocellular carcinoma and biliary tract cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate clinical data on the use of systemic treatment approaches for patients with early or intermediate-stage HCC
  • Plan optimal, individualized therapy approaches using immune checkpoint inhibitor–based regimens for patients with advanced or metastatic HCC, as clinically appropriate
  • Test tumors for biomarkers that can identify patients with hepatobiliary cancers suitable for targeted therapy
  • Select patients with hepatobiliary cancers most likely to benefit from immune checkpoint inhibitor–based combination therapy based on tumor characteristics, previous treatment, and patient characteristics and preferences
  • Develop strategies to identify and mitigate unique adverse events associated with immune checkpoint inhibitors and targeted therapies in patients with HCC or BTC

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.